Clinical Trial Update: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update showing termination of a study evaluating the combination of ipilimumab and MGN1703 in patients with advanced solid malignancies, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MGN1703 (MGN1703)
• ipilimumab (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cancers, Melanoma | Phase 1 | Status: TERMINATED